Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
Trading-Depot
>
18.03.2025 16:45:04

EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

18.03.2025 / 16:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling were re-elected to the Supervisory Board.

At the time of voting 63,8 % of the share capital was represented.

Dr. Michael Majerus, Chairman of the Supervisory Board, stated: "I am particularly pleased that the Annual General Meeting elected Dr. Anna Eichhorn and Mr. Stephen Catling to the Supervisory Board for an additional term. With their outstanding expertise, both are an integral part of the Supervisory Board's work. Majerus continued: "In the past financial year 2023/24, we were able to successfully prepare and conclude two benchmark transactions together with the Executive Board and thus significantly advance the Company's strategic development."

With the publication of the 3M numbers for the financial year 2024/25, the company forecast for the full year a high single-digit to low double-digit percentage increase in sales and an adjusted EBITDA margin of around 10 % in the core segment BRAINBiocatalysts.

In his address to shareholders, CEO Adriaan Moelker said: “Last year was in many respects a year of execution for BRAIN Biotech, as we prepared our path to consistently deliver on our goals. We announced the agreement with Royalty Pharma, which can bring BRAIN Biotech up to 129 million Euro in cash. Shortly thereafter, we announced the licensing agreement with Akribion Therapeutics. Taken together, these two transactions represent tremendous value for our shareholders.”

The detailed voting results and all other documents relating to the Annual General Meeting are available on the website of BRAIN Biotech AG: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2025 .

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.

 

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

 

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

 

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Group

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

 

Biocatalysts Ltd (Production, Distribution)

Website: https://www.biocatalysts.com/

LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn

 

BRAIN Biotech Zwingenberg (Technologies & R&D Services)

Website: www.brain-biotech.com

LinkedIn: BRAIN Biotech Technologies & Services

 

AnalyticonDiscovery (R&D)

Web: https://ac-discovery.com/

LinkedIn: https://www.linkedin.com/company/analyticon-discovery/

 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

 

 



18.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.com
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2102590

 
End of News EQS News Service

2102590  18.03.2025 CET/CEST

Analysen zu BRAIN Biotech AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Krypto-ETPs erklärt: Risiken, Chancen & Markttrends | BX Swiss TV

📈 Krypto ETPs in der Schweiz: So funktionieren sie wirklich! | Experteninterview mit Rechtsanwalt Luca 🇨🇭💼

Krypto ETPs werden in der Schweiz immer beliebter – aber was steckt rechtlich eigentlich hinter diesen Produkten? Und wodurch unterscheiden sie sich von ETFs oder Kryptofonds? In diesem spannenden Experteninterview bei klärt David Kunz (COO der BX Swiss) mit Rechtsanwalt Luca Bianchi (Partner bei Kellerhals Carrard) alle wichtigen Fragen zur Regulierung, Strukturierung und Besicherung von Krypto-ETPs.

📊 Ein Muss für alle, die sich für digitale Vermögenswerte, strukturierte Produkte und Krypto-Investments interessieren – ob Privatanleger oder institutionelle Investoren!

👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!

Krypto-ETPs erklärt: Risiken, Chancen & Markttrends | BX Swiss TV

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’581.93 18.88 BP9SUU
Short 13’828.61 13.86 BU9S6U
Short 14’407.17 8.63 UJ1BSU
SMI-Kurs: 13’052.03 18.03.2025 17:30:00
Long 12’540.00 19.37
Long 12’180.00 13.72
Long 11’740.00 8.60
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}